Processing

Please wait...

Settings

Settings

Goto Application

1. EP3189067 - RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE

Office
European Patent Office
Application Number 15766697
Application Date 04.09.2015
Publication Number 3189067
Publication Date 12.07.2017
Publication Kind B1
IPC
C07K 14/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/49
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
48Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus
49Lentiviridae, e.g. immunodeficiency viruses such as HIV, visna-maedi virus, equine infectious anaemia virus
CPC
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2740/16022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/16122
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16134
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants US HEALTH
Inventors KWONG PETER
PANCERA MARIE
ZHOU TONGQING
GEORGIEV IVELIN
JOYCE MICHAEL GORDON
ACHARYA PRIYAMVADA
GORMAN JASON
YANG YONGPING
DRUZ ALIAKSANDR
STEWART-JONES GUILLAUME
CHEN RITA
CHUANG GWO-YU
CHENG CHENG
BAXA ULRICH
MASCOLA JOHN
LYNCH REBECCA
ZHANG BAOSHAN
Designated States
Priority Data 201462046059 04.09.2014 US
201562136480 21.03.2015 US
Title
(DE) REKOMBINANTE HIV-1 HÜLLPROTEINE UND DEREN VERWENDUNG
(EN) RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
(FR) PROTÉINES DE L'ENVELOPPE DU VIH-1 ET LEUR UTILISATION
Abstract
(EN) HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.
(FR) L'invention concerne des trimères de l'ectodomaine Env du VIH-1 stabilisés sous une conformation fermée mature de préfusion, ainsi que leurs méthodes d'utilisation et leurs procédés de production. Dans plusieurs modes de réalisation, les trimères de l'ectodomaine Env du VIH-1 et/ou les molécules d'acide nucléique peuvent être utilisés pour générer une réponse immunitaire contre le VIH-1 chez le patient. Dans d'autres modes de réalisation, la quantité thérapeutiquement efficace des trimères de l'ectodomaine Env du VIH-1 peut être administrée au patient dans le cadre d'une méthode de traitement ou de prévention d'une infection à VIH-1.
Related patent documents